GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON

British Journal of Cancer

Volumn 89, Issue 7, 2003, Pages 1290-1297

  Hoskin, P J ^a   Sibtain, A ^a   Daley, F M ^b   Wilson, G D ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Carbonic anhydrase IX; Glucose transporter protein 1 (GLUT1); Hypoxia; Pimonidazole

Indexed keywords

CARBOGEN; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; CD34 ANTIGEN; CELL MARKER; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; KI 67 ANTIGEN; NICOTINAMIDE; PIMONIDAZOLE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; DRUG BINDING; DRUG MIXTURE; GEOGRAPHY; HUMAN; HUMAN TISSUE; HYPOXIA; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; RADIATION DOSE; RADICAL RADIOTHERAPY WITH CARBOGEN AND NICOTINAMIDE; RETROSPECTIVE STUDY; STAINING; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; TREATMENT FAILURE; VALIDATION PROCESS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; COHORT STUDIES; DNA-BINDING PROTEINS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0242298213     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601260     Document Type: Article

References (36)

1. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C (2001) Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7: 928-934
2. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104: 85-91
3. Baer S, Casaubon L, Schwartz MR, Marcogliese A, Younes M (2002) Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 112: 393-396
4. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL (2002) Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497
5. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289
6. Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6: 157-162
7. Chang S, Lee S, Lee C, Kim JI, Kim Y (2000) Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology 55: 448-452
8. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19: 3660-3668
9. De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG (1995) Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 36: 183-188
10. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998
11. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47
12. Hockel M, Vaupel P (2001) Biological consequences of tumor hypoxia. Semin Oncol 28: 36-41
13. Hoskin PJ, Saunders MI, Dische S (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer 86: 1322-1328
14. Hoskin PJ, Saunders MI, Phillips H, Cladd H, Powell ME, Goodchild K, Stratford MR, Rojas A (1997) Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer 76: 260-263
15. Hoskin PJ, Sibtain A, Dakey FM, Wilson GD (2003) The immunohistochemical assessment of hypoxia vojulently and proliferation in bladder carcinoma (submitted for publication).
16. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, de Wilde PC, Bussink J, Raleigh JA, van der Kogel AJ (2002) Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62: 7066-7074
17. Lara PC, Rey A, Santana C, Afonso JL, Diaz JM, Gonzalez GJ, Apolinario R (1998) The role of Ki67 proliferation assessment in predicting local control in bladder cancer patients treated by radical radiation therapy. Radiother Oncol 49: 163-167
18. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399
19. Maciejewski B, Majewski S (1991) Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21: 163-170
20. Moonen L, vd Voet H, de Nijs R, Hart AA, Horenblas S, Bartelink H (1998a) Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol 49: 149-155
21. Moonen L, vd Voet H, de Nijs R, Horenblas S, Hart AA, Bartelink H (1998b) Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 42: 525-530
22. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lindegaard JC, Davidson SE, Varia M, West C, Hunter R, Overgaard J, Raleigh JA (2001) Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 49: 581-586
23. Nordsmark M, Overgaard M, Overgaard J (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39
24. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61: 8924-8929
25. Overgaard J, Horsman MR (1996) Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6: 10-21
26. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, Abboh CC, Mazerolles C, Chopin DK (1997) The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80: 1472-1481
27. Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA (2001) Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 49: 569-574
28. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, Zorcher T, Fursich D, Papadopoulos T, Dunst J, Schrott KM, Sauer R (2000) Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 46: 1213-1221
29. Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H (1997) Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 10: 1128-1133
30. Semenza GL (2000) Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 59: 47-53
31. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482
32. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86: 1276-1282
33. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler Jr WC, Raleigh JA (1998) Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 71: 270-277
34. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083
35. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80: 1046-1051
36. Younes M, Juarez D, Lechago LV, Lerner SP (2001) Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 21: 575-578